Placental cell treatment to prevent kidney injury after heart surgery
Part of Heart & circulation, Kidney & urinary clinical trials.
This study tests an experimental treatment using special cells from donated placentas, given through an IV, to help prevent kidney damage that can occur after heart surgery. It is for patients at high risk of acute kidney injury, a sudden loss of kidney function that can happen after the stress of surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 45 years of age or older.
- You weigh at least 110 pounds (50 kg) and no more than 330 pounds (150 kg), and your body mass index (BMI) is below 40.
- Your kidney function is not severely reduced (eGFR is 30 or higher) and you are not on dialysis.
- You are scheduled for heart surgery that uses a heart-lung machine, and you have a high risk of developing acute kidney injury (a sudden drop in kidney function) after surgery.
- You do not have active bleeding, a bleeding disorder, or very low platelet counts.
- You are not pregnant, planning to become pregnant, or nursing, and if you can become pregnant, you agree to use highly effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment called RenalGuard to help protect your kidneys from damage that can happen after heart surgery. It may be helpful if you have certain risk factors like diabetes or kidney disease.
This study looks at a protein in the blood that may help predict kidney damage after heart surgery. It aims to find ways to protect kidney function during and after the operation.
This trial looks at whether a specific heart-surgery technique (called CLCVP) can help protect kidney function soon after surgery. It is mainly for adults with otherwise normal kidney tests before certain types of heart operations.
This study tests a new drug (ENN0403) given during heart surgery to see if it prevents acute kidney injury—a sudden drop in kidney function. The trial is for people who are already at higher risk due to their specific heart surgery and other health factors.
This study tests whether a drug called R2R01 can help protect your kidneys during major heart surgery. Heart surgery can sometimes damage the kidneys, and this trial is looking to see if this new medication reduces that risk.
This Phase 2 trial tests an LSALT peptide given around the time of “on-pump” heart surgery to help prevent or reduce acute kidney injury (a sudden drop in kidney function). It may help people who are at higher risk for kidney injury during or after surgery.
Hear when a new Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.